drugset / Trial / NCT05057052
Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus regorafenib for patients with colorectal cancer liver metastasis in the third-line setting.
Timeline
- Start
- 2021-09-26
- Primary completion
- 2026-09-25
- Completion
- 2026-09-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 80 mg | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |